Neos Therapeutics Announces Settlement With Teva on Cotempla XR-ODT Patent Litigation; Co. Has Granted Teva Right To Manufacture Its Generic Version Of XR-ODT Beginning In 2026 Or Earlier
Benzinga Newsdesk